CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that it has commenced an underwritten public offering of 7,000,000 shares of its common stock. All of these shares are being sold by Alnylam.
